Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women
about
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activityHormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysisLong-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west UgandaTopical microbicides for prevention of sexually transmitted infectionsBlocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responsesAdvances in HIV microbicide developmentMicrobicides: a new hope for HIV preventionMicrobicides and their potential as a catalyst for multipurpose sexual and reproductive health technologiesAntibodies for HIV prevention in young womenStampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDSTriple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticlesThe lantibiotic peptide labyrinthopeptin A1 demonstrates broad anti-HIV and anti-HSV activity with potential for microbicidal applicationsA multi-targeted drug candidate with dual anti-HIV and anti-HSV activityDevelopment of HIV-1 rectal-specific microbicides and colonic tissue evaluationDevelopment of a composite measure of product adherence, protocol compliance, and semen exposure using DNA and protein biomarkers for topical HIV prevention studiesFormulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatisThe Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal ApplicationsThe Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product DevelopmentSPL7013 Gel (VivaGelĀ®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humansThe effect of HIV counselling and testing on HIV acquisition in sub-Saharan Africa: a systematic reviewEnding the pandemic: reducing new HIV infections to zeroWomen and HIV in Sub-Saharan Africa.HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities.Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.Overview of microbicides for the prevention of human immunodeficiency virus.The importance of the vaginal delivery route for antiretrovirals in HIV prevention.Controlling the HIV/AIDS epidemic: current status and global challengesClosing the door to human immunodeficiency virus.Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trialEstimating the effectiveness in HIV prevention trials by incorporating the exposure process: application to HPTN 035 data.Impact of targeted counseling on reported vaginal hygiene practices and bacterial vaginosis: the HIV Prevention Trials Network 035 study.Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial.State of the science of adherence in pre-exposure prophylaxis and microbicide trials.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Contraception and pregnancy in microbicide trials.HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificitiesPerformance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediatorsBacterial vaginosis and the risk of trichomonas vaginalis acquisition among HIV-1-negative women.Topical microbicides and HIV prevention in the female genital tractComparison of closed-ended, open-ended, and perceived informed consent comprehension measures for a mock HIV prevention trial among women in Tanzania.
P2860
Q21133918-7BB39D97-7EEC-4CFC-8912-AB2F64E8A0F7Q21144588-ECACD435-752D-400B-9644-14474BBDFCEFQ21203732-EB40E70F-47A6-44B4-BD2B-7D11288AEA5FQ24202832-C3A4ED67-837A-4DE9-8D59-B2C4BDF7CBBDQ26774878-4BCABDF0-0251-48FD-9DD7-FD03F37B9A3EQ26852858-5B7B812E-9292-4075-9EB9-1D9A1805155AQ27022779-A7632C8D-56F7-4CDB-A803-C6ACCE3F3D46Q27026257-F8D00DA7-9C53-455D-A0E7-786FF74F3912Q28082033-E3BC4D15-B07C-414D-9EE6-592EF737FDB6Q28260539-3AE8735D-0532-4C4D-9931-8F6AD4222DE2Q28393885-6C35C6C9-F5FF-41D5-861F-77788FA7F48EQ28533345-FB630316-9A9F-4F6E-88EC-55072FFDD38CQ28534866-85F1FC61-8595-4BED-8FFC-90C3EEE8287AQ28540761-B20AA1A3-2011-4750-AE3E-C4B3CB6F5E16Q28542608-32B32D37-F426-4943-AC66-97A4E7B0226FQ28544625-2468D381-B14E-4653-B0C3-3AC81DDB76ADQ28546014-17731209-BE22-421C-B681-8604AD975217Q28551783-B78545FE-79F2-412B-88B6-78422470126FQ28740364-4688C58A-929C-4A5A-BEAA-5B60FF65F2A1Q30248456-838C8BCD-172E-40CA-8FD2-395A8349F616Q30356525-23B659D9-2AD3-4185-8514-2521235E6E59Q30356708-F3540801-0CC0-4F96-8A73-838F89D7333DQ30383181-7C72BBE6-2B4C-4AEE-8A9E-7296AD52CD68Q30412592-FD5F133F-6FE1-4F3B-BCDE-27607053C24AQ30413777-E97EB3EC-4D9E-4C50-BB44-8A0ED13EEAC3Q30414890-067B3AC5-EB29-43B2-BED0-1A5C798347A7Q30420558-9427086D-FA7A-48FD-A949-EBB23878ABB5Q30428089-37A1EF6D-A544-4E04-819E-DF6DF9C30D32Q30572895-619CE034-083D-452F-8F46-25CB96470670Q30824899-AF9BDB89-F905-4094-BBEA-6C3339DB03CDQ30831315-F80BBE7C-5291-47BE-A9F8-150731C74815Q31014284-E76FD522-2915-4048-B449-097F75331E89Q33798685-A00883E4-63AE-4A4B-A9AB-C82203A77820Q33821090-9E8039D4-C9F5-4A2F-8F5A-380859BB4AE0Q33924850-26407FA2-66D7-40C0-A032-C91C4D6E03D3Q33939974-B9F3E23A-97CB-4878-B7C5-D2922DE73EDAQ33999185-90376A43-D8F8-4DD3-82CF-81FCF325B036Q34025858-4A653134-2036-4746-93BF-299F40FBA5E6Q34086820-B6D559D1-1A55-4AC1-A662-66ABD99113DAQ34089917-449E829D-A03D-49DB-8DC9-96A89D7C2810
P2860
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women
description
2011 nĆ® lÅ«n-bĆ»n
@nan
2011 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Ō±ÕŗÖÕ«Õ¬Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2011 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ”ÕŗÖÕ«Õ¬Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2011幓ć®č«ę
@ja
2011幓č«ę
@yue
2011幓č«ę
@zh-hant
2011幓č«ę
@zh-hk
2011幓č«ę
@zh-mo
2011幓č«ę
@zh-tw
2011幓č®ŗę
@wuu
name
Safety and effectiveness of Bu ...... tion of HIV infection in women
@ast
Safety and effectiveness of Bu ...... tion of HIV infection in women
@en
Safety and effectiveness of Bu ...... tion of HIV infection in women
@nl
type
label
Safety and effectiveness of Bu ...... tion of HIV infection in women
@ast
Safety and effectiveness of Bu ...... tion of HIV infection in women
@en
Safety and effectiveness of Bu ...... tion of HIV infection in women
@nl
prefLabel
Safety and effectiveness of Bu ...... tion of HIV infection in women
@ast
Safety and effectiveness of Bu ...... tion of HIV infection in women
@en
Safety and effectiveness of Bu ...... tion of HIV infection in women
@nl
P2093
P2860
P50
P1433
P1476
Safety and effectiveness of Bu ...... tion of HIV infection in women
@en
P2093
Albert Profy
Anne Coletti
Barbra A Richardson
BenoĆ®t MĆ¢sse
HIV Prevention Trials Network (HPTN) 035 Study Team
Irving F Hoffman
Lisa Maslankowski
Lydia Soto-Torres
Muzala Kapina
Sharon L Hillier
P2860
P304
P356
10.1097/QAD.0B013E32834541D9
P407
P577
2011-04-01T00:00:00Z